Antiangiogenic drugs for colorectal cancer: Exploring new possibilities

Clinical Colorectal Cancer

Volumn 12, Issue 1, 2013, Pages 1-7

  Ferrarotto, Renata ^a   Hoff, Paulo M ^a,b  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Aflibercept; Bevacizumab; Cediranib; Metastatic colorectal cancer; Vatalanib

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BRIVANIB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CEDIRANIB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ABDOMINAL PAIN; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTERIAL THROMBOEMBOLISM; ASTHENIA; BLEEDING; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; COLORECTAL CANCER; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL PAIN; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; ISCHEMIA; LIVER METASTASIS; LIVER RESECTION; MAINTENANCE CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 4 CLINICAL TRIAL; PROTEINURIA; REVIEW; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TUMOR BLEEDING; TUMOR CELL; TUMOR MICROENVIRONMENT; ULCER; VOMITING;

EID: 84874677879     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2012.06.002     Document Type: Review

References (79)

1. A. Jemal, F. Bray, M.M. Center Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. A. Eichholz, S. Merchant, A.M. Gaya Anti-angiogenesis therapies: their potential in cancer management Onco Targets Ther 3 2010 69 82
3. J. Folkman Angiogenesis inhibitors: a new class of drugs Cancer Biol Ther 2 4 suppl 1 2003 S127 S133
4. K.J. Gotink, H.M. Verheul Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13 2010 1 14
5. G.N. Naumov, L.A. Akslen, J. Folkman Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch Cell Cycle 5 2006 1779 1787
6. I.P. Torres Filho, M. Leunig Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice Proc Natl Acad Sci U S A 91 1994 2081 2085
7. H.M. Verheul, E.E. Voest, R.O. Schlingemann Are tumours angiogenesis-dependent? J Pathol 202 2004 5 13
8. F. Fan, A. Schimming, D. Jaeger, K. Podar Targeting the tumor microenvironment: focus on angiogenesis J Oncol 2012 2012 281261
9. K. Mulder, S. Koski, A. Scarfe Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future Oncotarget 1 2010 515 529
10. S.C. Wei, P.N. Tsao, S.C. Yu Placenta growth factor expression is correlated with survival of patients with colorectal cancer Gut 54 2005 666 672
11. L.M. Ellis, D.G. Haller Bevacizumab beyond progression: does this make sense? J Clin Oncol 26 2008 5313 5315
12. L.M. Ellis, D.J. Hicklin VEGF-targeted therapy: mechanisms of anti-tumour activity Nat Rev Cancer 8 2008 579 591
13. J.P. O'Connor, R.A. Carano, A.R. Clamp Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging Clin Cancer Res 15 2009 6674 6682
14. M. Watanabe, J.L. Boyer, R. Crystal Genetic delivery of bevacizumab to suppress vascular endothelial growth factor-induced high-permeability pulmonary edema Hum Gene Ther 20 2009 598 610
15. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
16. G. Klement, S. Baruchel, J. Rak Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity J Clin Invest 105 2000 R15 R24
17. E. Van Cutsem, J. Tabernero, R. Lakomy C Allegra, intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): results of a multinational phase III trial (EFC10262-VELOUR) Ann Oncol 18 2011 abstract O-0024
18. K.J. Kim, B. Li, J. Winer Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 1993 841 844
19. C.G. Lee, M. Heijn, E. di Tomaso Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions Cancer Res 60 2000 5565 5570
20. C.S. Fuchs, J. Marshall, E. Mitchell Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study J Clin Oncol 25 2007 4779 4786
21. L.B. Saltz, S. Clarke, E. Díaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
22. B.J. Giantonio, P.J. Catalano, N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200 J Clin Oncol 25 2007 1539 1544
23. S. Welch, K. Spithoff, R.B. Rumble, J. Maroun Gastrointestinal Cancer Disease Site Group Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review Ann Oncol 21 2010 152 162
24. D. Cunningham, R.P. Wong, G. D'haens A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): final PFS results J Clin Oncol 26 2008 abstract 4028
25. P.M. Hoff, A. Hochhaus, B.C. Pestalozzi Cediranib + FOLFOX/XELOX versus placebo + FOLFOX/XELOX in patients (pts) with previously untreated meta-static colorectal cancer: a randomized, double blind, phase III study (HORIZON II) Ann Oncol 21 suppl 8 2010 abstract LBA19
26. A. Fielding, P.M. Hoff, L. Pike Exploration of the effect of treatment to progression with the VEGF signaling inhibitor cediranib (CED) plus chemotherapy (CT) on the results of the HORIZON (HZ) II trial in first-line metastatic colorectal cancer J Clin Oncol 29 suppl 15 2011 abstract:e14052 www.asco.org Accessed: June 7, 2012
27. H.J. Schmoll, D. Cunningham, A. Sobrero MFOLFOX 6 + cediranib vs MFOLFOX 6 + bevacizumab in previously untreated metastatic colorectal cancer. (mCRC): A randomized, double blind, phase II/III study (HORIZON III) Ann Oncol 21 suppl 8 2010 abstract 580O
28. Recentin did not meet primary endpoint in Horizon III study in metastatic colorectal cancer [press release] March 8, 2010 Astra Zeneca http://www.astrazeneca.com/Media/Press-releases/Article/20100308-RECENTIN-did- not-meet-primary-endpoint-in-Horizon-III Accessed: June 7, 2012
29. AstraZeneca announces results of recentin HORIZON II phase III trial in metastatic colorectal cancer [press release] May, 2010 Astra Zeneca http://www.astrazeneca.com/Media/Press-releases/Article/20100528-AstraZeneca- Announces-Results-of-Recentin-HORIZON-II- Accessed: June 23, 2012
30. J.R. Hecht, T. Trarbach, J.D. Hainsworth Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma J Clin Oncol 29 2011 1997 2003
31. E. Van Cutsem, E. Bajetta, J. Valle Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma J Clin Oncol 29 2011 2004 2010
32. J.R. Hecht, T. Yoshino, E.P. Mitchell A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): interim results J Clin Oncol 28 suppl 15 2010 abstract 3532
33. L.B. Saltz, L.S. Rosen, J.L. Marshall Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy J Clin Oncol 25 2007 4793 4799
34. B. Samson, J. Latreille, N.T. Nguyen A phase II study with sunitinib and capecitabine in patients with metastatic colorectal cancer (MCRC) refractory to previous treatment with 5FU/irinotecan/oxaliplatin J Clin Oncol 29 2011 abstract 545 www.asco.org Accessed: June 7, 2012
35. A. Grothey, J.M. Lafky, B.W. Morlan Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): results of the phase II North Central Cancer Treatment Group study N054C J Clin Oncol 28 suppl 2010 abstract 3549 www.asco.org Accessed: June 7, 2012
36. M. Ychou, O. Bouche, S. Thézenas Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS-mutated tumors (mt; NEXIRI) J Clin Oncol 29 suppl 2011 abstract e14002 www.asco.org Accessed: June 7, 2012
37. C.R. Garrett, L.L. Siu, A. El-Khoueiry Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of Brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy Br J Cancer 105 2011 44 52
38. J.D. Shapiro, L.L. Siu, J.R. Zalcberg A phase III study of cetuximab (CET) plus either Brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): the NCIC CTG/AGITG CO.20 trial J Clin Oncol 29 suppl 2011 abstract TPS163
39. A study in second line metastatic colorectal cancer http:// clinicaltrials.gov/ct2/show/NCT01183780?term=ramucirumab&rank=15 Accessed: June 23, 2012
40. R. Garcia-Carbonero A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784 J Clin Oncol 30 (suppl): abstract 533 www.asco.org Accessed: June 7, 2012
41. J.L. Spratlin, R.B. Cohen, M. Eadens Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 J Clin Oncol 28 2010 780 787
42. A. Grothey, A.F. Sobrero, S. Siena CORRECT Study Team Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies J Clin Oncol 30 suppl 2012 abstract LBA385 www.asco.org Accessed: June 7, 2012
43. V. Brower Antiangiogenesis research is booming, as questions and studies proliferate J Natl Cancer Inst 101 2009 780 781
44. A. Grothey, M.M. Sugrue, D.M. Purdie Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 2008 5326 5334
45. A.L. Cohn, T. Bekaii-Saab, J.C. Bendell Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP) J Clin Oncol 28 suppl 2010 abstract 3596 www.asco.org Accessed: June 7, 2012
46. A. Grothey, T. Bekaii-Saab, H. Hurwitz Cumulative exposure to bevacizumab (BV) after progression correlates with increased survival in patients (pts) with metastatic colorectal cancer (mCRC): a time-dependent analysis of the ARIES observational cohort study Eur J Cancer 47 2011 abstract 6013
47. S. Kopetz, J.L. Abbruzzese Hidden biases in an observational study of bevacizumab beyond progression J Clin Oncol 27 2009 1732 1733 author reply:1733
48. S.R. Brave, C. Eberlein, M. Shibuya Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model Angiogenesis 13 2010 337 347
49. J. Tabernero, E. Van Cutsem, R. Lakomy Results from VELOUR, a phase 3 study of aflibercept (A) versus placebo (pbo) in combination with FOLFIRI for the treatment of patients (pt) with previously treated metastatic colorectal cancer (MCRC) Eur J Cancer 47 2011 abstract 6LBA
50. C.J. Allegra, G. Yothers, M.J. O'Connell Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08 J Clin Oncol 29 2011 11 16
51. A. de Gramont, E. Van Cutsem, J. Tabernero AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer J Clin Oncol 29 suppl 2011 abstract 362 www.asco.org Accessed: June 7, 2012
52. E. Mitry, A. Fields, H. Bleiberg Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer A meta-analysis of two randomized trials J Clin Invest 25 2006 abstract 3524
53. E.E. Voest, N. Snoeren, S.B. Schouten A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer J Clin Oncol 29 suppl 2011 abstract 3565 www.asco.org Accessed: June 7, 2012
54. N.E. Kemeny, W.R. Jarnagin, M. Capanu Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer J Clin Oncol 29 2011 884 889
55. L.H. Simkens, J. Tol, L.W. Terstappen The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab Ann Oncol 21 2010 2447 2448
56. A.J. Weickhardt, D. Williams, C. Lee Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): analysis of the phase III MAX study J Clin Oncol 29 suppl 2011 abstract 3531 www.asco.org Accessed: June 7, 2012
57. M. Pohl, N. Werner, J. Munding Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature Z Gastroenterol 49 2011 1398 1406
58. H.J. Schmoll, P.M. Hoff, J.D. Robertson Association of baseline CEA, VEGF, and soluble VEGF receptor-2 with treatment outcomes in two randomized phase III trials of cediranib in metastatic colorectal cancer (mCRC) J Clin Oncol 29 suppl 2011 abstract 3590 www.asco.org Accessed: June 7, 2012
59. K.H. Bramswig, G.W. Prager, A. Martel A predictive role of carcinoembryonic antigen (CEA) for therapeutic efficacy of angiogenesis- targeting therapy in colorectal cancer: novel clinical observation based upon recently discovered CEA biology J Clin Oncol 28 suppl 2010 abstract 3574 www.asco.org Accessed: June 7, 2012
60. S. Matsusaka, Y. Mishima, M. Suenaga Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab Cancer 117 2011 4026 4032
61. M. Ronzoni, M. Manzoni, S. Mariucci Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients Ann Oncol 21 2010 2382 2389
62. V. Goede, O. Coutelle, J. Neuneier Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy Br J Cancer 103 2010 1407 1414
63. M. Suenaga, S. Matsusaka, M. Ueno Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients Surg Today 41 2011 1067 1074
64. S. Kopetz, P.M. Hoff, J.S. Morris Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance J Clin Oncol 28 2010 453 459
65. S. Kopetz, H.T. Tran, D. Cunningham Association of circulating cytokine and angiogenic factors. (CAFs) with outcomes to second-line FOLFOX plus bevacizumab or cediranib in metastatic colorectal cancer J Clin Oncol 29 suppl 2011 abstract 406 www.asco.org Accessed: June 7, 2012
66. F. Loupakis, C. Cremolini, A. Fioravanti Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer Br J Cancer 104 2011 1262 1269
67. J. Sastre, M. Vidaurreta, A. Gómez Role of baseline circulating tumour cells and KRas status in patients with metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab: a TTD Spanish group cooperative study Eur J Cancer 47 2011 abstract 6004
68. J.M. Jürgensmeier, P.M. Hoff, L. Pike Use of KRAS mutation status to predict clinical outcomes in patients with metastatic colorectal cancer (mCRC) treated with the VEGF signaling inhibitor cediranib J Clin Oncol 29 15 2011 suppl 3613
69. T. Watanabe, T. Kobunai, Y. Yamamoto Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients Dis Colon Rectum 54 2011 1026 1035
70. L. Xu, D.G. Duda, E. di Tomaso Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer Cancer Res 69 2009 7905 7910
71. P.P. Grimminger, M. Shi, C. Barrett TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials Pharmacogenomics J 12 2012 404 411
72. O. Mir, R. Coriat, L. Cabanes An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity Oncologist 16 2011 1325 1332
73. R. Ryanne Wu, P.A. Lindenberg, R. Slack Evaluation of hypertension as a marker of bevacizumab efficacy J Gastrointest Cancer 40 2009 101 108
74. P. Bono, J. Rautiola, T. Utriainen Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma Acta Oncol 50 2011 569 573
75. B.I. Rini, D.P. Cohen, D.R. Lu Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 2011 763 773
76. S. Szmit, P. Langiewicz, J. Złnierek Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines Kidney Blood Press Res 35 2011 18 25
77. Y. Hirashima, Y. Yamada, U. Tateishi Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis Int J Cancer 130 2011 2359 2365
78. J.P. O'Connor, C.J. Rose, A. Jackson DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6 Br J Cancer 105 2011 139 145
79. B. Guiu, J.M. Petit, F. Bonnetain Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer Gut 59 2010 341 347